This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

47/100

✓ Peer-reviewed alzhub usefulness score 47 out of 100. Tau biomarkers

Topic: Amyloid, tau and blood-test diagnosis

Background and purpose This study was undertaken to compare the performance of plasma p-tau181 with that of [ 18 F]fluorodeoxyglucose (FDG) positron emission tomography (PET) in the identification of early biological Alzheimer disease (AD). Methods We included 533 cognitively impaired participants from the Alzheimer's Disease Neuroimaging Initiative. Participants underwent PET scans, biofluid collection, and cognitive tests.

Key findings

Methods We included 533 cognitively impaired participants from the Alzheimer's Disease Neuroimaging Initiative.
Participants underwent PET scans, biofluid collection, and cognitive tests.
Receiver operating characteristic analyses were used to determine the diagnostic accuracy of plasma p-tau181 and [ 18 F]FDG-PET using clinical diagnosis and core AD biomarkers ([ 18 F]florbetapir-PET and cerebrospinal fluid [CSF] p-tau181) as reference standards.
Differences in the diagnostic accuracy between plasma p-tau181 and [ 18 F]FDG-PET were determined by bootstrap-based tests.

Why it matters

A blood test for phosphorylated tau181 identified early Alzheimer's disease better than a brain scan measuring glucose metabolism in 533 people with cognitive impairment. This concerns diagnosis, not treatment or prevention.

New to this subject? Start with our plain-English guide: Blood tests & biomarkers →

Study details

Participants533
Evidence strengthLow

How this study scored 47/100

Published in a peer-reviewed journal. Scored zero for study design, effect reported and randomised / blinded because the record does not state it. We have no data on senior author's track record, so that was left out: it earned 45 of the 96 points we could judge it on, which is 47 out of 100.

Component	Points	Why
Journal tier	7 / 10	Tier 3 — peer-reviewed journal (European journal of neurology)
Journal's citation record	2 / 4	European Journal of Neurology: journal h-index 181 (OpenAlex, 2026-10-29)
Study design	0 / 12	No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence	1 / 5	Rated “low” in our summary
Peer-review validation	10 / 10	Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent	4 / 5	2024 — within 3 year(s) of the newest study here
Sample size	2 / 4	533 participants
Effect reported	0 / 3	No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people	3 / 3	Studied in people (participant count stated)
Randomised / blinded	0 / 2	No randomisation or blinding stated — scores zero (not stated in the record — scored 0)
Times cited	2 / 7	Cited 10 times (OpenAlex, 2026-10-10)
Citations per year	1 / 5	2.5 citations a year over 4 year(s) since 2024
Impact for its field and year	2 / 6	Cited 2.7× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here	1 / 6	Cited by 2 other studies in this library
Still being cited	1 / 4	Cited 10 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record	— / 4	Senior author's record not available — left out of this score
Institution's track record	2 / 3	University College London: institution h-index 2,029 (OpenAlex)
Multi-centre collaboration	3 / 3	OpenAlex lists 18 institution(s) in 6 countries
Indexed in PubMed	2 / 2	Indexed in PubMed (PMID 39447157)
Free to read	2 / 2	Free to read
Points	45 / 96	Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 45 of the 96 points we could judge it on is 47 out of 100.
Total	47 / 100	—

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.

APA 7th

Quispialaya, K. M., Therriault, J., Aliaga, A., Tissot, C., Servaes, S., Rahmouni, N., et al. (2024). Plasma phosphorylated tau181 outperforms [18F] fluorodeoxyglucose positron emission tomography in the identification of early Alzheimer disease. European journal of neurology. https://doi.org/10.1111/ene.16255

Vancouver

Quispialaya KM, Therriault J, Aliaga A, Tissot C, Servaes S, Rahmouni N, et al. Plasma phosphorylated tau181 outperforms [18F] fluorodeoxyglucose positron emission tomography in the identification of early Alzheimer disease. European journal of neurology. 2024. doi:10.1111/ene.16255. PMID: 39447157.

BibTeX

@article{quispialaya2024-39447157,
  author  = {Quispialaya, K. M. and Therriault, J. and Aliaga, A. and Tissot, C. and Servaes, S. and Rahmouni, N. and Karikari, T. K. and Benedet, A. L. and others},
  title   = {{Plasma phosphorylated tau181 outperforms [18F] fluorodeoxyglucose positron emission tomography in the identification of early Alzheimer disease}},
  journal = {European journal of neurology},
  year    = {2024},
  doi     = {10.1111/ene.16255},
  pmid    = {39447157},
  url     = {https://doi.org/10.1111/ene.16255}
}

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 28.

Later studies that cite this one

2 studies in the alzhub library list this one in their references.

Related studies in Tau biomarkers

Also tagged “phosphorylated”

732 studies in the library carry the topic tag “phosphorylated”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 732 tagged studies.

Similar studies

More on Tau biomarkers

See all studies in Tau biomarkers →